NCT01081028: Connect® MM- The Multiple Myeloma Disease Registry
Updated: Sep 27, 2022
NCT01081028: Connect® MM- The Multiple Myeloma Disease Registry
The purpose of the Connect® MM Registry is to explore the natural history and real world management of patients with newly diagnosed symptomatic multiple myeloma (MM) and provide unique insights into the management of MM and the impact of this hematologic disorder on patients.
Sponsor:
ClinicalTrials.gov Identifier: NCT01081028
Connect® MM- The Multiple Myeloma Disease Registry
First Posted : March 5, 2010
The Importance of Establishing Baseline Disease Characteristics.
Clin Lymphoma Myeloma Leuk. 2015 Jun
Click here for details
Connect MM is the first and largest observational, noninterventional, prospective registry of patients newly diagnosed with multiple myeloma (NDMM) in the United States. It collects longitudinal data on patients within clinical practice including patients in clinical trials.
Recognition of early mortality in multiple myeloma by a prediction matrix.
Am J Hematol. 2017 Sep
Click here for details
Heterogeneity of Second-Line Treatment for Patients With Multiple Myeloma in the Connect MM Registry (2010-2016).
Click here for details
Clin Lymphoma Myeloma Leuk. 2018 Jul
Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM.
Blood Adv. 2018 Jul
Click here for details
Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM Registry.
Ann Hematol. 2018 Dec
Click here for details
CONNECT MM Registry Investigators. Treatment Journeys of Patients With Newly Diagnosed Multiple Myeloma (NDMM): Results From The Connect MM Registry.
Clin Lymphoma Myeloma Leuk. 2020 May
Click here for details
Connect MM Registry Investigators. Association between race and treatment patterns and survival outcomes in multiple myeloma: A Connect MM Registry analysis.
Cancer. 2020 Oct
Click here for details
CONNECT MM Registry Investigators. Effect of initial treatment on health-related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant intent: results from the Connect(®) MM Registry.
Br J Haematol. 2021 Apr
Click here for details
Treatment Outcomes and Health Care Resource Utilization in Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide-only Maintenance, Any Maintenance, or No Maintenance: Results from the Connect MM Registry.
Clin Ther. 2018 Jul
Click here for details
Analysis of Common Eligibility Criteria of Randomized Controlled Trials in Newly Diagnosed Multiple Myeloma Patients and Extrapolating Outcomes.
Clin Lymphoma Myeloma Leuk. 2017 Sep
Click here for details
CONNECT MM Registry Investigators. Development of a prognostic model for overall survival in multiple myeloma using the Connect(®) MM Patient Registry.
Br J Haematol. 2019 Dec
Click here for details
Real-World Evaluation of Health-Related Quality of Life in Patients With Multiple Myeloma From Germany.
Clin Lymphoma Myeloma Leuk. 2021 Feb
Click here for details
Connect MM Registry Investigators. Connect MM Registry as a national reference for United States multiple myeloma patients.
Cancer Med. 2020 Jan
Click here for details
117 Real-World Treatment Patterns and Clinical, Economic, and Humanistic Burden in Triple-Class Refractory Multiple Myeloma: Analysis of the Connect® Multiple Myeloma (MM) Disease Registry
Program: Oral and Poster Abstracts
Type: Oral
Session: 905. Outcomes Research- Lymphoid Malignancies: Multiple Myeloma and Other Plasma Cell Disorders
Hematology Disease Topics & Pathways:
Clinical Research, Health Outcomes Research, Plasma Cell Disorders, Diseases, Real World Evidence, Registries, Lymphoid Malignancies, Clinical Practice (e.g. Guidelines, Health Outcomes and Services, and Survivorship, Value; etc.)
Saturday, December 11, 2021: 10:00 AM
11/04/2021: PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced the presentation of research across a wide range of hematologic diseases at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, which will take place in Atlanta, Georgia, and virtually, from December 11 to 14, 2021. Data from more than 80 company-sponsored studies will be featured, including 23 oral presentations, highlighting key research and development programs in lymphomas, leukemias, multiple myeloma and myeloid diseases, and showcasing our commitment to delivering transformative medicines across major hematologic diseases.
Real-World Treatment Patterns and Clinical, Economic, and Humanistic Burden in Triple-Class Refractory Multiple Myeloma: Analysis of the CONNECT® Multiple Myeloma (MM) Disease Registry
Click here for details.